{"id":"NCT02033889","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12-13","primaryCompletion":"2017-08-03","completion":"2017-08-03","firstPosted":"2014-01-13","resultsPosted":"2018-09-10","lastUpdate":"2018-09-10"},"enrollment":621,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Ertugliflozin 5 mg","otherNames":["MK-8835"]},{"type":"DRUG","name":"Ertugliflozin 15 mg","otherNames":["MK-8835"]},{"type":"DRUG","name":"Placebo to Ertugliflozin","otherNames":[]},{"type":"OTHER","name":"Glimepiride","otherNames":["Amaryl","GLIMPID","GLIMY"]},{"type":"DRUG","name":"Placebo to Glimepiride","otherNames":[]},{"type":"BIOLOGICAL","name":"Basal Insulin","otherNames":["Insulin glargine","Insulin detemir","NPH insulin","Degludec"]},{"type":"DRUG","name":"Metformin","otherNames":["Glucophage XR","Carbophage SR","Riomet","Fortamet","Glumetza","Obimet","Gluformin","Dianben","Diabex","Diaformin","Siofor","Metfogamma"]}],"arms":[{"label":"Ertuglifozin 5 mg","type":"EXPERIMENTAL"},{"label":"Ertugliflozin 15 mg","type":"EXPERIMENTAL"},{"label":"Placebo/Glimepiride","type":"PLACEBO_COMPARATOR"}],"summary":"This is an efficacy and safety study of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy. The primary study hypothesis is that at Week 26, the mean reduction from baseline in hemoglobin A1c (HbA1c) for ertugliflozin is greater than that for placebo.","primaryOutcome":{"measure":"Change From Baseline in A1C at Week 26 (Excluding Rescue Approach)","timeFrame":"Baseline and Week 26","effectByArm":[{"arm":"Placebo/Glimepiride","deltaMin":-0.03,"sd":null},{"arm":"Ertugliflozin 5 mg","deltaMin":-0.73,"sd":null},{"arm":"Ertugliflozin 15 mg","deltaMin":-0.91,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28857451","36763328","34213819","32648108","32372382","32324082","32324065","32236732","31797522","31064361","30614616"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":209},"commonTop":["Upper respiratory tract infection","Hypoglycaemia","Viral upper respiratory tract infection","Back pain","Urinary tract infection"]}}